[1]. First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lung cancer (Amsterdam, Netherlands) [巻]201 [頁]108109 (2025年) [査読] 有
[DOI] [2]. 皮膚科医に知ってほしい肺サルコイドーシス
皮膚科 [巻]6 [号]4 [頁]389 -394 (2024年) [査読] 有
[3]. Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study
BMC pulmonary medicine [巻]24 [号]1 [頁]495 (2024年) [査読] 有
[4]. 臨床薬理の進歩 2024(45号)
(2024年) [査読] 有
[5]. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [頁]JCO2400278 (2024年) [査読] 有
[機関リポジトリ]